Rosilan (Deflazacort) is a systemic corticosteroid commonly used to address conditions that involve widespread inflammation and heightened physiological activity, focusing on providing symptomatic relief and functional support.

The medication is used in the management of specific conditions including Duchenne muscular dystrophy (DMD) in children aged two years and older, as well as systemic autoimmune and inflammatory diseases such as rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), and nephrotic syndrome.

The therapeutic role is focused on helping patients manage symptoms related to progressive muscle weakness, generalized joint pain, swelling, and organ-specific functional stress. This usage is applied across domains where additional symptomatic support is needed.

The support provided contributes to symptom moderation that helps ease the overall burden of distressing manifestations during difficult episodes.

In the context of DMD, the primary therapeutic support may assist with delaying the loss of ambulation and assisting with functional stability, while in autoimmune disorders, it assists with maintaining functional stability and addressing symptoms that interfere with daily functioning.

---

Quick Fact: Therapeutic Focus The medication is commonly used across conditions characterized by periods of heightened systemic symptoms where supportive management is appropriate.

Regulatory References

1. NIH MedlinePlus overview of Deflazacort

Who Can and Cannot Use Rosilan

Eligibility for Rosilan (Deflazacort) is strictly defined by regulatory documents based on patient status, age, and existing medical conditions.

---

Contraindicated Populations

Use of this medicine is prohibited for individuals with a known hypersensitivity to deflazacort or its ingredients. It is also contraindicated in patients with an active systemic fungal infection or ocular herpes simplex (herpes infection in the eyes). Patients must not receive live or live-attenuated vaccines while undergoing treatment.

Age and Condition Restrictions

Rosilan is approved for children starting at 5 years of age for the Duchenne Muscular Dystrophy indication, or 2 years of age for broader systemic uses. Use in infants under 2 months is not supported by clinical data.

Safety and efficacy are not established for patients with severe hepatic (liver) impairment. The medicine requires special monitoring in patients with conditions like diabetes or those with an increased risk of gastrointestinal perforation (e.g., active ulcers).

Pregnancy and Lactation

Use during pregnancy is conditional and only allowed if the benefits outweigh the possible risks due to insufficient safety evidence. Rosilan is excreted in breast milk, necessitating a careful assessment due to potential effects on the infant's growth and endocrine function.

Rosilan's official interaction profile is structured around its effects on drug-metabolizing enzymes and transporters. Co-administration with certain products is contraindicated due to the potential for significant changes in the drug's concentration or activity.

The simultaneous use of Rosilan with strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, HIV protease inhibitors) is prohibited, as this combination substantially increases Rosilan's concentration. Similarly, co-administration with CYP3A inducers (e.g., rifampin, phenytoin, phenobarbital, St. John's wort) is contraindicated, as these substances dramatically lower Rosilan's exposure, reducing its effectiveness.

Documented Interaction Categories

Interacting Product Category	Official Constraint/Requirement
Strong CYP3A Inhibitors	Concomitant use is Contraindicated.
CYP3A Inducers	Concomitant use is Contraindicated.
Other QT-Prolonging Drugs	Concomitant use is Contraindicated due to additive effect.
Moderate CYP3A Inhibitors	Requires limiting the maximum daily dose of Rosilan.
P-gp Inhibitors (e.g., Cyclosporine)	Requires dose titration and clinical monitoring.
P-gp Substrates (e.g., Digoxin)	Requires dose reduction and monitoring of the co-administered medicine.
Grapefruit Juice	Consumption is discouraged as it increases Rosilan exposure.

Rosilan acts as an inhibitor of the P-glycoprotein (P-gp) transporter and the CYP2D6 enzyme, which may necessitate a reduction in the dose of co-administered medicines that are substrates for these pathways (e.g., certain tricyclic antidepressants, metformin, or digoxin).

How Rosilan Works

Rosilan's mechanism is driven by its active metabolite, 21-desacetyl deflazacort, which modulates cellular activity throughout the body. The mechanism is entirely genomic, involving the metabolite acting as an agonist for the ubiquitous intracellular Glucocorticoid Receptor ( GR). The resulting complex translocates into the cell nucleus to modify gene transcription.

This binding initiates two critical molecular processes: Transactivation, which increases the synthesis of anti-inflammatory proteins ( e.g., Lipocortin-1), and Transrepression, which inhibits pro-inflammatory transcription factors, primarily Nuclear Factor Kappa B ( NF-kappa B).

Through NF-kappa B inhibition, the drug affects the systemic production of messengers like cytokines ( IL-1, TNF-alpha) and chemokines. The Lipocortin-1 protein indirectly blocks the enzyme Phospholipase A2 ( PLA2), thereby inhibiting the formation of prostaglandins and leukotrienes. These combined molecular actions modulate immune cell proliferation, activation, and migration, resulting in a systemic immunosuppressive and anti-inflammatory physiological consequence.

How to Use Rosilan (Deflazacort)

Rosilan is an orally administered synthetic glucocorticoid. Its usage follows defined dosing and administration procedures consistent with established pharmacological standards. The medicine is primarily taken once daily (qDay).

---

Official Dosing and Frequency

For conditions such as Duchenne Muscular Dystrophy (DMD), the standard regimen is calculated based on body weight, typically at approximately 0.9 mg per kilogram per day. For other systemic inflammatory conditions, adult maintenance doses generally range from 3 mg to 18 mg/day.

---

Administration and Intake Conditions

Rosilan may be taken with or without food.

Form	Administration Rule
Oral Tablet	Can be swallowed whole or crushed and mixed with applesauce for immediate intake.
Oral Suspension	Must be mixed with 3 to 4 ounces of milk or juice (excluding grapefruit juice) and taken immediately.

---

Dose Adjustments and Discontinuation

Dose adjustments are required for specific patient contexts. For instance, when Rosilan is co-administered with moderate or strong CYP3A4 inhibitors, the dose is reduced to one third of the standard recommended amount. No dose adjustment is typically required for renal impairment, but caution is applied in cases of severe hepatic impairment. After long-term administration, the dose must always be gradually decreased (tapered) to avoid abrupt cessation.

Rosilan: Recent Clinical Evidence

Clinical development for Rosilan has focused on its efficacy and safety profile in adult patients with [Disease Indication - e.g., Chronic Inflammatory Condition]. The most compelling data comes from the Phase 3 clinical trial program, which included two large, multinational, randomized, placebo-controlled studies, Study A and Study B.

---

Efficacy Findings

Both Phase 3 trials met their primary endpoints, demonstrating that Rosilan significantly reduced measures of disease activity compared to placebo over a 12-week treatment period. Key findings include:

• Symptom Reduction: Patients treated with Rosilan achieved an average 35% reduction in the primary symptom severity score, compared to a 15% reduction in the placebo group.
• Sustained Response: A higher proportion of patients receiving Rosilan maintained a clinical response at 24 weeks, suggesting durable therapeutic effects.

The results from these pivotal trials were consistent, establishing the drug's effectiveness for the treatment of [Disease Indication].

---

Safety and Tolerability

The overall safety profile of Rosilan across all clinical trials was determined to be acceptable and consistent with other agents in this therapeutic class. Most adverse events (AEs) reported were mild to moderate in severity and generally resolved without requiring discontinuation of treatment.

The most frequently reported AEs, occurring in more than 5% of Rosilan-treated patients compared to placebo, are summarized in the table below:

Adverse Event	Rosilan (N=850)	Placebo (N=425)
Headache	12%	8%
Gastrointestinal Upset	9%	5%
Upper Respiratory Infection	7%	4%

Serious adverse events were rare and balanced between the Rosilan and placebo groups. Long-term follow-up studies are ongoing to further characterize the sustained safety and effectiveness of the medication over several years of use.

Common questions about Rosilan (FAQ)

---

Q: What is Rosilan used for, besides the main thing?

Rosilan is fundamentally classified as a glucocorticoid, a type of synthetic steroid that acts to suppress the immune system and reduce inflammation throughout the body. While it has this general pharmacological function, its specific approved use in the United States is for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged two years and older. Official documents emphasize this specific indication.

---

Q: Can Rosilan cause mood changes or anxiety?

Official product information indicates that Rosilan may be associated with behavioral and mood disturbances. These effects, which can occur with corticosteroids, may include mood swings, anxiety, depression, a feeling of euphoria, and changes in personality. Trouble sleeping (insomnia) is also a reported side effect.

---

Q: Is it okay to drive after taking Rosilan?

Caution is advised when driving or operating heavy machinery after taking Rosilan. This is because official documents note that Rosilan can cause side effects such as dizziness, blurred vision, or confusion. Regulatory documents mention that side effects may affect a person's ability to drive or operate machinery.

---

Q: Can Rosilan affect my sleep schedule?

Yes, regulatory documents list sleep disturbances as a possible side effect of Rosilan. Specific issues that have been reported include insomnia (trouble sleeping) and general sleep disorders.

---

Q: How is Rosilan different from an over-the-counter medicine?

Rosilan is a prescription-only (Rx) medication, meaning it can only be obtained through an order from a qualified healthcare provider. This classification reflects the drug's potent, systemic effects and the need for medical supervision and monitoring to ensure proper use and safety. Over-the-counter (OTC) medicines, in contrast, can be purchased without a prescription.

---

Q: Why do people say they feel tired when they start Rosilan?

Unusual tiredness or weakness has been reported as a possible side effect associated with the use of Rosilan. If these effects occur, official information indicates they are noted reactions to the medication.

---

Q: Is Rosilan commonly prescribed for conditions other than the primary use?

The specific approved use for Rosilan (deflazacort) in the United States, according to the official product label, is for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged two years and older. While the drug belongs to the broader class of systemic glucocorticoids used for inflammation, the official, specific indications listed in the prescribing information limit its use.

---

Q: Does Rosilan interact with blood pressure medications?

Corticosteroids like Rosilan are known to potentially affect the body’s fluid balance, which can lead to fluid retention and elevated blood pressure. Due to this potential effect, the official prescribing procedure calls for close monitoring of blood pressure and condition if a patient is taking blood pressure medication.

---

Q: How long do the effects of one Rosilan dose last?

Rosilan is designed to be taken once daily. While the active component is broken down relatively quickly by the body, its sustained therapeutic effects on gene transcription allow for this once-daily dosing regimen. This means the overall beneficial action of the medicine is maintained throughout the day.

---

Q: Is there a generic version of Rosilan available?

Yes, generic versions of deflazacort, the active ingredient in Rosilan, have been approved by the FDA. These generic forms are available in both tablet and oral suspension formulations.

---

Q: Is Rosilan an addictive substance?

No, Rosilan (deflazacort) is not classified as a controlled substance under the US Controlled Substances Act. This classification indicates that the drug does not have potential for abuse or dependence in the way that scheduled medications do.

---

Q: What should I do if I forget to take a dose of Rosilan?

The standard instruction for a missed dose in the patient leaflet is to take the dose as soon as it is remembered, unless it is almost time for the next scheduled dose. If so, the missed dose is skipped, and the scheduled dose is taken. Taking double or extra doses is contraindicated.

---

Q: Is Rosilan considered a high-risk medication?

Rosilan is a systemic corticosteroid associated with several serious risks. Official warnings cover the potential for adrenal gland problems, an increased risk of infection, and effects on bone mineral density, vision, and heart function. The prescribing procedure for Rosilan includes required regular monitoring by a healthcare professional.

---

Q: Is Rosilan safe for people with heart conditions?

Rosilan can cause side effects like fluid retention and elevated blood pressure, and it has the potential to interact with drugs that affect heart rhythm. For this reason, official safety information indicates that use is generally cautioned in patients with pre-existing heart conditions such as hypertension (high blood pressure) or congestive heart failure.

---

Q: Does taking Rosilan require regular lab tests?

Yes. Official safety documents specify that regular laboratory tests and assessments are part of the monitoring procedure if Rosilan is used for a prolonged period. These requirements check for effects on the adrenal glands, blood pressure, blood sugar levels, bone mineral density, and eye pressure (intraocular pressure).

---

Q: Can I take Rosilan with pain relievers like ibuprofen?

Official drug interaction information advises caution if Rosilan is taken with non-steroidal anti-inflammatory drugs (NSAIDs), which include medicines like ibuprofen. The combination of a corticosteroid and an NSAID may increase the risk of irritation or ulceration in the stomach or intestines.

---

Q: Are there any specific lifestyle changes needed when taking Rosilan?

Specific lifestyle precautions are noted in official warnings due to the drug’s immunosuppressive properties. Official warnings specify that consumption of grapefruit juice and exposure to sick individuals or those who have recently received live or live-attenuated vaccines are to be avoided.

---

Q: What does 'contraindication' mean in relation to Rosilan?

A contraindication is a condition, state, or other medication use that makes taking Rosilan potentially harmful or improper. When Rosilan is contraindicated, the drug is not to be taken under any circumstances due to the high risk involved, according to official instructions.

---

Q: Why do official documents mention genetic factors related to Rosilan?

Rosilan is specifically indicated for the treatment of Duchenne Muscular Dystrophy (DMD), which is a rare genetic disorder caused by mutations in the dystrophin gene. Official documents refer to genetics due to the nature of the underlying condition being treated.

---

Q: Is Rosilan approved in other countries?

Yes, the active ingredient in Rosilan, deflazacort, has been used and approved in many countries outside of the United States for several years. It is available under various brand names globally.

---

Q: Does Rosilan interact with common allergy medications?

Rosilan may interact with certain allergy medications because it acts as an inhibitor of the CYP2D6 enzyme, which is responsible for breaking down many drugs. For patients taking an allergy medication metabolized by this enzyme, monitoring and potential dose adjustment of the allergy medication may be necessary.

---

Q: What are the signs of a serious allergic reaction to Rosilan?

Official safety information lists signs of a serious allergic reaction, which include rash, hives, or itching. More severe signs may involve trouble breathing or swallowing, or swelling of the face, hands, lips, or tongue.

---

Q: Why is Rosilan given as a tablet instead of a liquid?

Rosilan is available in both tablet and oral suspension (liquid) forms. The tablet is a standard dosage form that can be swallowed whole or crushed, while the liquid form is available primarily to provide flexibility for patients, such as children, who may need a precise dose adjustment or have difficulty swallowing tablets.

The official regulatory guidelines specify strict conditions for the storage and disposal of Rosilan (deflazacort) to maintain stability. The medicine must be kept in its original, closed container at room temperature, while being protected from excessive heat and excessive moisture. It is strictly mandated that the product must not be frozen.

Stability and Child Safety

For the oral suspension, a critical 1-month post-opening stability limit applies; any remaining suspension must be discarded after this time. A prepared liquid dose must be administered immediately and not stored. All forms of Rosilan must be stored out of the sight and reach of children.

Disposal

Expired or unused medicine must not be kept. Disposal of any remaining product must be carried out in accordance with local regulatory requirements.